Payment overview · 2025
General Payments
$696.83
38 reported records · 15 companies
Healthcare provider profile · identity verified
Alfred Darrell Johnson, MD
Allopathic & Osteopathic Physicians|Internal Medicine · JEFFERSON CITY, MO · NPI 1396900510
Verified facts
What the public records show
CMS Open Payments records show Alfred Darrell Johnson, MD received $696.83 in general payments during 2025 across 38 reported records.
PFIZER INC. accounted for 27.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 25 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Symbicort by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 109 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $189.13 | 27.1% | 12 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $96.07 | 13.8% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $59.48 | 8.5% | 3 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $59.25 | 8.5% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $55.07 | 7.9% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $48.03 | 6.9% | 3 | 2025 |
| Collegium Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $42.18 | 6.0% | 2 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $30.35 | 4.4% | 2 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $20.28 | 2.9% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $20.19 | 2.9% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $17.87 | 2.6% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $17.24 | 2.5% | 1 | 2025 |
| SANOFI PASTEUR INC. | Unresolved — no canonical attribution shown | $16.45 | 2.4% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $13.63 | 2.0% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $11.61 | 1.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $696.83 | 38 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $141.07 | 9 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $141.07 | 9 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $96.07 | 4 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $59.48 | 3 | 2025 |
Source payment records
|
|||||
| BEXSERO Normalized: bexsero |
Biological | GlaxoSmithKline, LLC. | $48.03 | 3 | 2025 |
Source payment records
|
|||||
| Jornay PM Normalized: jornay pm |
Drug | Collegium Pharmaceutical, Inc. | $42.18 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $39.68 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $35.92 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $34.63 | 2 | 2025 |
Source payment records
|
|||||
| PENMENVY Normalized: penmenvy |
Biological | GlaxoSmithKline, LLC. | $34.21 | 2 | 2025 |
Source payment records
|
|||||
| Edwards SAPIEN 3 Ultra Transcatheter Heart Valve Normalized: edwards sapien 3 ultra transcatheter heart valve |
Device | Edwards Lifesciences Corporation | $31.81 | 1 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $30.35 | 2 | 2025 |
Source payment records
|
|||||
| EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Normalized: edwards sapien 3 transcatheter heart valve thv |
Device | Edwards Lifesciences Corporation | $27.44 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $20.28 | 1 | 2025 |
Source payment records
|
|||||
| ENFLONSIA Normalized: enflonsia |
Drug | Merck Sharp & Dohme LLC | $20.19 | 1 | 2025 |
Source payment records
|
|||||
| VAXNEUVANCE Normalized: vaxneuvance |
Biological | Merck Sharp & Dohme LLC | $20.19 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $19.15 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $19.15 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $17.87 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $17.24 | 1 | 2025 |
Source payment records
|
|||||
| BEYFORTUS Normalized: beyfortus |
Biological | SANOFI PASTEUR INC. | $16.45 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $13.63 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $13.45 | 1 | 2025 |
Source payment records
|
|||||
| VYNDAQEL Normalized: vyndaqel |
Drug | PFIZER INC. | $13.43 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $11.61 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 109 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
45 | 12 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
109 | 14 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
63 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 369 | 93 |
| Levothyroxine Sodium | Levothyroxine Sodium | 277 | 64 |
| Omeprazole | Omeprazole | 256 | 61 |
| Hydrochlorothiazide | Hydrochlorothiazide | 226 | 52 |
| Losartan Potassium | Losartan Potassium | 214 | 49 |
| Lisinopril | Lisinopril | 171 | 48 |
| Glimepiride | Glimepiride | 166 | 39 |
| Amlodipine Besylate | Amlodipine Besylate | 155 | 43 |
| Simvastatin | Simvastatin | 140 | 33 |
| Gabapentin | Gabapentin | 126 | 32 |
| Montelukast Sodium | Montelukast Sodium | 125 | 29 |
| Alprazolam | Alprazolam | 118 | 21 |
| Pantoprazole Sodium | Pantoprazole Sodium | 113 | 34 |
| Ozempic | Semaglutide | 109 | 14 |
| Metformin Hcl | Metformin Hcl | 106 | 25 |
| Tramadol Hcl | Tramadol Hcl | 102 | 18 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 101 | 29 |
| Citalopram Hbr | Citalopram Hydrobromide | 94 | 19 |
| Meloxicam | Meloxicam | 91 | 27 |
| Metoprolol Tartrate | Metoprolol Tartrate | 91 | 23 |
| Pravastatin Sodium | Pravastatin Sodium | 87 | 25 |
| Metoprolol Succinate | Metoprolol Succinate | 76 | 18 |
| Tamsulosin Hcl | Tamsulosin Hcl | 75 | 19 |
| Allopurinol | Allopurinol | 74 | 21 |
| Furosemide | Furosemide | 73 | 23 |
| Trazodone Hcl | Trazodone Hcl | 73 | 12 |
| Lovastatin | Lovastatin | 70 | 15 |
| Metformin Hcl Er | Metformin Hcl | 70 | 16 |
| Carvedilol | Carvedilol | 69 | 18 |
| Fluticasone Propionate | Fluticasone Propionate | 66 | 18 |
| Clopidogrel | Clopidogrel Bisulfate | 63 | 14 |
| Eliquis | Apixaban | 63 | 14 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 60 | 19 |
| Alendronate Sodium | Alendronate Sodium | 60 | 13 |
| Buspirone Hcl | Buspirone Hcl | 60 | 14 |
| Atenolol | Atenolol | 56 | 12 |
| Potassium Chloride | Potassium Chloride | 54 | 17 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 50 | suppressed |
| Mirtazapine | Mirtazapine | 49 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 47 | 16 |
| Pregabalin | Pregabalin | 47 | suppressed |
| Lorazepam | Lorazepam | 45 | suppressed |
| Synthroid | Levothyroxine Sodium | 45 | 12 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 43 | 12 |
| Fenofibrate | Fenofibrate | 42 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 42 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 40 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 39 | 11 |
| Ezetimibe | Ezetimibe | 39 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 39 | suppressed |
| Bupropion Xl | Bupropion Hcl | 38 | suppressed |
| Diazepam | Diazepam | 38 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 38 | suppressed |
| Memantine Hcl | Memantine Hcl | 37 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 37 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 33 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 33 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 33 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 33 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 32 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 30 | suppressed |
| Famotidine | Famotidine | 30 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 29 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 29 | suppressed |
| Trulicity | Dulaglutide | 28 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 27 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 26 | suppressed |
| Xarelto | Rivaroxaban | 26 | suppressed |
| Finasteride | Finasteride | 25 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 24 | suppressed |
| Jardiance | Empagliflozin | 24 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 24 | suppressed |
| Mounjaro | Tirzepatide | 24 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 24 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 23 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 23 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 23 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 22 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 22 | suppressed |
| Topiramate | Topiramate | 22 | suppressed |
| Clonazepam | Clonazepam | 21 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 21 | suppressed |
| Gemfibrozil | Gemfibrozil | 20 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 20 | suppressed |
| Vascepa | Icosapent Ethyl | 20 | suppressed |
| Baclofen | Baclofen | 19 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 18 | suppressed |
| Spironolactone | Spironolactone | 18 | suppressed |
| Aripiprazole | Aripiprazole | 17 | suppressed |
| Bumetanide | Bumetanide | 17 | suppressed |
| Estradiol | Estradiol | 17 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 17 | suppressed |
| Lamotrigine | Lamotrigine | 17 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 16 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 16 | suppressed |
| Risperidone | Risperidone | 16 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 16 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 16 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Azithromycin | Azithromycin | 14 | 13 |
| Linzess | Linaclotide | 14 | suppressed |
| Nystatin | Nystatin | 14 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 14 | suppressed |
| Phenobarbital | Phenobarbital | 14 | suppressed |
| Ramipril | Ramipril | 14 | suppressed |
| Rybelsus | Semaglutide | 14 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Chlorthalidone | Chlorthalidone | 13 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 13 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 13 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 12 | suppressed |
| Glipizide Er | Glipizide | 12 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 12 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 12 | suppressed |
| Trandolapril-Verapamil Er | Trandolapril/Verapamil Hcl | 12 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 12 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 11 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 11 | suppressed |
| Januvia | Sitagliptin Phosphate | 11 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 11 | suppressed |
| Mupirocin | Mupirocin | 11 | suppressed |
| Silodosin | Silodosin | 11 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $696.83 · 38 records | PFIZER INC. | ABRYSVO, AUSTEDO XR, Auvelity, BEXSERO, BEYFORTUS, BREZTRI, CAPLYTA, Dexcom G6 Transmitter, EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV), ENFLONSIA, Edwards SAPIEN 3 Ultra Transcatheter Heart Valve, Jornay PM, NURTEC ODT, Ozempic, PENMENVY, PREVNAR 20, QULIPTA, Rybelsus, TRINTELLIX, UBRELVY, VAXNEUVANCE, VOQUEZNA, VYNDAQEL, Wegovy, ZAVZPRET | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error